A closer look at YY1: A drug target and biomarker for the treatment of neurodegenerative diseases

Target Name: YY1

NCBI ID: G7528

Content of Review Report on YY1 Target / Biomarker

YY1

A closer look at YY1: A drug target and biomarker for the treatment of neurodegenerative diseases

Neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's have a significant impact on the daily life of millions of people worldwide. These debilitating conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms such as cognitive decline, motor dysfunction, and behavioral changes.

One of the major challenges in the treatment of neurodegenerative diseases is the lack of effective therapies that can slow down or halt the progression of the disease. While there are currently available treatments that can manage symptoms, there is a growing need for new and more effective therapies that can treat the underlying causes of these conditions.

YY1, a protein that is expressed in the brain, has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases. In this article, we will explore the research on YY1 and its potential as a drug target and biomarker.

The discovery of YY1

YY1, which stands for Yang-Yu-1, was first identified as a protein that is expressed in the brain and is highly expressed in the frontal cortex, the part of the brain responsible for executive functions such as decision-making, planning, and impulse control.

The identification of YY1 was made using a technique called transcriptomics, which involves the analysis of the expression of genes in the brain. Researchers found that YY1 was expressed in the frontal cortex and was highly co-expressed with other proteins involved in brain function, such as the neurotransmitter dopamine.

YY1's unique expression patterns and its co-expression with other brain-derived proteins make it an attractive candidate for further study as a drug target or biomarker.

The potential benefits of YY1 as a drug target

YY1 has been shown to play a role in a number of important brain functions, including the regulation of synaptic plasticity, the formation of new neurons, and the regulation of neurotransmitter release. Its expression patterns and its co-expression with other brain-derived proteins make it an attractive candidate for the development of new therapeutics for a variety of neurodegenerative diseases.

One of the potential benefits of YY1 as a drug target is its potential to treat a range of neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms such as cognitive decline, motor dysfunction, and behavioral changes.

YY1 has been shown to be involved in the regulation of the aggregation of beta-amyloid peptides, which are a hallmark of Alzheimer's disease. By targeting YY1, researchers may be able to reduce the formation of beta-amyloid peptides and slow down or halt the progression of Alzheimer's disease.

YY1 has also been shown to play a role in the regulation of neurotransmitter release and the modulation of synaptic plasticity. These processes are important for the formation of new neurons and the regulation of learning and memory. By targeting YY1, researchers may be able to treat neurodegenerative diseases by increasing the number of new neurons that are formed, improving synaptic plasticity, and enhancing learning and memory.

The potential benefits of YY1 as a biomarker

YY1 has also been identified as a potential biomarker for the treatment of neurodegenerative diseases. By measuring the expression of YY1 in the brain, researchers may be able to monitor the effectiveness of new treatments and determine whether the treatments are having the desired effect.

YY1 has been shown to be a reliable biomarker for the diagnosis of Alzheimer's disease, with higher levels of YY1 expression being associated with greater severity of the disease. This suggests that measuring the expression of YY1 may be a useful diagnostic tool for

Protein Name: YY1 Transcription Factor

Functions: Multifunctional transcription factor that exhibits positive and negative control on a large number of cellular and viral genes by binding to sites overlapping the transcription start site (PubMed:15329343, PubMed:17721549, PubMed:24326773, PubMed:25787250). Binds to the consensus sequence 5'-CCGCCATNTT-3'; some genes have been shown to contain a longer binding motif allowing enhanced binding; the initial CG dinucleotide can be methylated greatly reducing the binding affinity (PubMed:15329343, PubMed:17721549, PubMed:24326773, PubMed:25787250). The effect on transcription regulation is depending upon the context in which it binds and diverse mechanisms of action include direct activation or repression, indirect activation or repression via cofactor recruitment, or activation or repression by disruption of binding sites or conformational DNA changes (PubMed:15329343, PubMed:17721549, PubMed:24326773, PubMed:25787250). Its activity is regulated by transcription factors and cytoplasmic proteins that have been shown to abrogate or completely inhibit YY1-mediated activation or repression (PubMed:15329343, PubMed:17721549, PubMed:24326773, PubMed:25787250). For example, it acts as a repressor in absence of adenovirus E1A protein but as an activator in its presence (PubMed:1655281). Acts synergistically with the SMAD1 and SMAD4 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression (PubMed:15329343). Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions (PubMed:15329343). May play an important role in development and differentiation. Proposed to recruit the PRC2/EED-EZH2 complex to target genes that are transcriptional repressed (PubMed:11158321). Involved in DNA repair (PubMed:18026119, PubMed:28575647). In vitro, binds to DNA recombination intermediate structures (Holliday junctions). Plays a role in regulating enhancer activation (PubMed:28575647)

The "YY1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YY1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets